Person:
TAŞAN, ERTUĞRUL

Loading...
Profile Picture

Status

Organizational Units

Organizational Unit

Job Title

First Name

ERTUĞRUL

Last Name

TAŞAN

Name

Email Address

Birth Date

Search Results

Now showing 1 - 10 of 26
  • Publication
    Effects of Weight Loss with Bariatric Surgery on Platelet Count and Volume
    (2018-07-01) Ilhan, Muzaffer; KARAMAN, ÖZCAN; Yasin, Ayse Irem; TURGUT, SEDA; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; YASİN, AYŞE İREM; TURGUT, SEDA; TAŞAN, ERTUĞRUL
    Objective: Obesity is a chronic metabolic disorder that leads to the increased risk of cardiovascular diseases. This study aims to investigate the effect of weight loss on the platelet count and volume, which is associated with cardiovascular diseases. Methods: In total, 56 obese patients were recruited for the study. The parameters were retrospectively evaluated before and after 6 months of surgery. Results: The mean weight of the patients was 126.2±23.1 kg before surgery and 91.8±20.5 kg after surgery (p<0.001). The mean platelet counts were 292.5±58.6×10³/µL before surgery and 246.8±59.1×10³/µL after surgery (p<0.001). The mean platelet volumes were 10.4±1.0 fL and 11.6±0.9 fL before and after surgery, respectively (p<0.001). The mean platelet counts before surgery were correlated with the mean platelet volume, mean weight, and mean body mass index (p<0.01, r=−0.39, p<0.01, r=0.35, p<0.01, r=0.41, respectively). The mean platelet counts after surgery were correlated with the mean platelet volume (p<0.001, r=−0.68). Conclusion: This study demonstrated decreased platelet counts and increased platelet volume at 6 months after surgery in obese patients. Further long-term and prospective studies are warranted to clarify these results and pathopsychological mechanisms involved.
  • Publication
    A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus
    (2016-03-01) Ilhan, MAHMUT MUZAFFER; Tiryakioglu, N. O.; KARAMAN, O.; Coskunpinar, E.; YILDIZ, R. S.; TURGUT, SEDA; Tiryakioglu, D.; TOPRAK, HÜSEYİN; TASAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TOPRAK, HÜSEYİN; TAŞAN, ERTUĞRUL
    Purpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI.
  • Publication
    An Unusual Case of Cushing’s Syndrome: Coexistence of Functional Pituitary and Adrenal Adenoma
    (2017-04-01) İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; YASİN ÇETİN, AYŞE İREM; BÜYÜKBAŞLI, NUR; HAMDARD, JAMSHİD; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    A case of adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome, which develops in the course of ACTH-dependent Cushing's disease, is presented in this report. A 47-year-old woman with a past history of surgery and gamma knife radiosurgery because of Cushing's disease was admitted to the endocrinology clinic with weight gain and unregulated blood glucose levels. Hypercortisolemia was still persisting and diagnostic work-up indicated ACTH-independent Cushing's syndrome. Along with the rare possibility of this coexistence, longstanding ACTH hypersecretion can play a role in functional transition of adrenal adenomas. Further studies are needed to clarify the underlying mechanisms.
  • Publication
    Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey
    (2015-01-01T00:00:00Z) Tasan, ERTUĞRUL; HANIMOGLU, Hakan; Turgut, SEDA; Ilhan, MAHMUT MUZAFFER; EVRAN, Sevket; KAYNAR, Mehmet Yasar; TAŞAN, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER
    Giant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.
  • Publication
    Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
    (2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    Objectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.
  • Publication
    Investigation of the Vitamin D Receptor Polymorphisms in Acromegaly Patients
    (2015-01-01) Ilhan, MAHMUT MUZAFFER; TOPTAS-HEKIMOGLU, Bahar; YAYLIM, Ilhan; Turgut, SEDA; TURAN, Saime; Karaman, Ozcan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    Objective. The genetic structural alterations in the majority of somatotroph adenomas are not clarified and the search for novel candidate genes is still a challenge.We aimed to investigate possible associations between vitamin D receptor (VDR) polymorphisms and acromegaly. Design, Patients, and Methods. 52 acromegaly patients (mean age 45.7 ± 1.9 years) and 83 controls (mean age 43.1 ± 2.6 years) were recruited to the study. VDR polymorphism was determined by polymerase chain reaction-based restriction fragment length polymorphism methods. Results. The distribution of VDR genotypes showed a significant difference in the frequencies of VDR FokI genotypes between patients and controls (𝑃 = 0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (𝑃 = 0.035) and carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly (OR: 1.5, 95% CI: 1.07–2.1; 𝑃 = 0.020). IGF1 levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype (𝑃 = 0.0049). 25(OH)D3 levels were significantly lower in acromegaly patients (𝑃 < 0.001). Conclusions. Our study suggests that VDR FokI genotypes might affect the development of acromegaly and VDR polymorphisms may play a role in the course of acromegaly as a consequence of altering hormonal status.
  • Publication
    The use of complementary medicine in patients with diabetes
    (2016-05-01) İLHAN, MAHMUT MUZAFFER; DEMİR, BÜŞRA; YÜKSEL, SENA; AYDIN ÇATAKLI, SERRA; YILDIZ, RABİA SEVDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    OBJECTIVE: Diabetes mellitus (DM) is a growing health problem with serious complications. The chronic and progressive nature of the disease often leads patients to use complementary and integrative medicine. The present study aimed to investigate the frequency of use of alternative medicine by patients with DM and the products used. METHODS: Between September 2014 and May 2015, 301 patients with DM were selected from Bezmialem Foundation University Hospital Diabetes Clinic to participate in the study. RESULTS: The results of the study indicate that 81 (26.9%) patients had tried alternative medicine, and 50 (16.6%) patients continued to use some form of alternative medicine product. A total of 43 (14.3%) patients used such products every day and 24 (8%) patients had used alternative medicine products for up to 6 months. Glycated hemoglobin (HbA1c) levels were significantly decreased in patients using alternative medicine products compared to the remainder of patients in the study (p=0.017). No other significant difference was found between the two groups. It was observed that among patients using alternative medicine products, only 10 (12%) had informed their physicians. CONCLUSION: This study indicated that patients with diabetes are very likely to use alternative medicine products. Additional studies are needed to further determine the efficacy of these products. Patients as well as health providers must be educated about complementary medicine and alternative products.
  • Publication
    Esophagus motility in overt hypothyroidism
    (2014-07-01) Ilhan, MAHMUT MUZAFFER; Arabaci, ELİF; Turgut, SEDA; Karaman, Ozcan; DANALIOGLU, Ahmet; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; ARABACI, ELİF; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    Purpose Gastrointestinal tract is one of the most affected systems in hypothyroidism. Despite decreased esophageal emptying, prolonged esophageal and gastric transit time have been indicated in previous reports, the mechanism of thyroid hormones activity and antibodies on the esophagus motility is not yet fully understood. This study was conducted to evaluate the esophagus motility by manometry in hypothyroid patients.
  • Publication
    The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage
    (2017-05-01) Turgut, SEDA; Ilhan, Muzaffer; Turan, Saime; Karaman, Ozcan; Yaylim, Ilhan; Kucukhuseyin, Ozlem; Tasan, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    Aim: Prolactinomas are thought to arise from clonal expansion of a single mutated cell which is subjected to growth stimuli of several permissive factors, although the pathogenetic mechanisms underlying tumorigenesis remain unclear. The present study aimed to investigate the role of p16 (540C→G and 580C→T) and mouse double minute 2 (MDM2) (SNP309T→G) gene polymorphisms in tumorigenesis and characteristics of prolactinoma. Patients and methods: A total of 74 patients with prolactinoma and 100 age- and gender-matched healthy individuals were enrolled in the study. Serum prolactin levels were measured by enzyme-linked immunosorbent assay (ELISA). p16 and MDM2 polymorphisms were determined by polymerase chain reaction-restriction fragment polymorphism and agarose gel electrophoresis. Results: p16 540C→G genotype distribution was found to be: CC: 66.2%, CG: 28.4%, GG: 5.4%; p16 580C→T genotype distribution was found to be: CC: 82.4%, CT: 17.6%, TT: 0% and MDM2 genotype distribution was found to be: TT: 31.1%, TG: 47.3%, GG: 21.6% in patients with prolactinoma. Tumor diameter before treatment was correlated with prolactin levels before treatment and percentage of prolactin decrease with treatment (r=0.719, p<0.001, p=0.034 r=0.256, respectively). The number of patients with tumor size decrease of more than 50% in those with homozygous genotype (TT+GG) of MDM2 SNP309T→G was significantly higher than in heterozygous genotype (TG) carriers (odds ratio(OR)=0.18, 95% confidence interval(CI)=0.06-0.58; p=0.003). Conclusion: This study showed that p16 and MDM2 polymorphisms do not play a decisive role in tumorigenesis, but some genotypes of these polymorphisms might be associated with follow-up characteristics of prolactinoma.
  • Publication
    The Correlation of Increased CRP Levels with NFKB1 and TLR2 Polymorphisms in the Case of Morbid Obesity
    (2016-11-01) Soydas, T.; Karaman, O.; Arkan, H.; Yenmis, G.; ILHAN, M. M.; Tombulturk, K.; TASAN, ERTUĞRUL; Sultuybek, G. Kanigur; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRUL
    Morbid obesity (MO) is associated with an increase in circulating levels of systemic acute phase proteins such as C-reactive protein (CRP). Toll-like receptor is possible candidate for inflammatory responses which is mainly mediated by NFKB1. The aim of this study was to investigate the relationship between NFKB1 and Toll-like receptor (TLR) 2 polymorphisms and the risk of MO in a Turkish population in the context of CRP serum levels which may contribute to susceptibility to the disease. We analysed the distribution of NFKB1-94 ins/del ATTG rs28362491 and TLR2 Arg753Gln rs5743708 polymorphisms using PCR-RFLP method and CRP serum levels using ELISA method in 213 MO and 200 healthy controls. The frequency of the ins/ins genotype and ins allele of rs28362491 was significantly higher in the patients compared to control group (P: 0.0309; P: 0.0421, respectively). Additionally, the frequency of GG genotype and G allele of rs5743708 was found to be statistically higher in the patient group (P: 0.0421; P < 0.0001, respectively). In addition, serum CRP levels (>20 mg/l) in MO patients with ins/ins genotype were significantly higher than in patients with del/ins genotype (P: 0.0309). Serum CRP levels were also higher in MO patients with GG genotype and G allele (P: 0.0001). According to combined analysis, the wild type of rs28362491 and rs5743708 polymorphisms (ins/ins/GG genotype) was also significantly higher in the patient group versus the control group when compared with the combined ins/ins/GA and del/ins/GA genotype (P < 0.0001). Therefore, our findings suggest that rs28362491 and rs5743708 polymorphisms were significantly associated with MO disease through acting by modulating serum CRP levels.